ME02851B - Verwendung von p3 aus bakteriophagenfusionsproteinen als amyloidbindemittel - Google Patents
Verwendung von p3 aus bakteriophagenfusionsproteinen als amyloidbindemittelInfo
- Publication number
- ME02851B ME02851B MEP-2017-215A MEP2017215A ME02851B ME 02851 B ME02851 B ME 02851B ME P2017215 A MEP2017215 A ME P2017215A ME 02851 B ME02851 B ME 02851B
- Authority
- ME
- Montenegro
- Prior art keywords
- seq
- amino acid
- disease
- fusion protein
- sek
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title claims 12
- 108020001507 fusion proteins Proteins 0.000 title claims 12
- 239000011230 binding agent Substances 0.000 title 1
- 241001515965 unidentified phage Species 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 claims 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 238000006467 substitution reaction Methods 0.000 claims 7
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 claims 2
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 102000029797 Prion Human genes 0.000 claims 2
- 108091000054 Prion Proteins 0.000 claims 2
- 206010002022 amyloidosis Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000006061 fatal familial insomnia Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000022099 Alzheimer disease 2 Diseases 0.000 claims 1
- 102000004321 Atrophin-1 Human genes 0.000 claims 1
- 108090000806 Atrophin-1 Proteins 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 102000012192 Cystatin C Human genes 0.000 claims 1
- 108010061642 Cystatin C Proteins 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 1
- 201000005505 Measles Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000033063 Progressive myoclonic epilepsy Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 claims 1
- YNDIAUKFXKEXSV-CRYLGTRXSA-N florbetapir F-18 Chemical compound C1=CC(NC)=CC=C1\C=C\C1=CC=C(OCCOCCOCC[18F])N=C1 YNDIAUKFXKEXSV-CRYLGTRXSA-N 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 238000002600 positron emission tomography Methods 0.000 claims 1
- 208000008864 scrapie Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261708709P | 2012-10-02 | 2012-10-02 | |
| US201261730316P | 2012-11-27 | 2012-11-27 | |
| US201361801349P | 2013-03-15 | 2013-03-15 | |
| US201361828105P | 2013-05-28 | 2013-05-28 | |
| PCT/US2013/062862 WO2014055515A1 (en) | 2012-10-02 | 2013-10-01 | Use of p3 of bacteriophage fusion proteins as amyloid binding agents |
| EP13776674.7A EP2906235B1 (de) | 2012-10-02 | 2013-10-01 | Verwendung von p3 aus bakteriophagenfusionsproteinen als amyloidbindemittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02851B true ME02851B (de) | 2018-04-20 |
Family
ID=61257143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-215A ME02851B (de) | 2012-10-02 | 2013-10-01 | Verwendung von p3 aus bakteriophagenfusionsproteinen als amyloidbindemittel |
Country Status (2)
| Country | Link |
|---|---|
| ME (1) | ME02851B (de) |
| RS (1) | RS56559B1 (de) |
-
2013
- 2013-10-01 ME MEP-2017-215A patent/ME02851B/de unknown
- 2013-10-01 RS RS20170941A patent/RS56559B1/sr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS56559B1 (sr) | 2018-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171413T1 (hr) | Upotreba p3 bakteriofagni fuziranih proteina kao amiloidnih vezujućih agenasa | |
| Mathis et al. | Small-molecule PET tracers for imaging proteinopathies | |
| Timmes et al. | Recombinant prion protein refolded with lipid and RNA has the biochemical hallmarks of a prion but lacks in vivo infectivity | |
| Huang et al. | Single-chain fragment variable passive immunotherapies for neurodegenerative diseases | |
| WO2015024668A3 (en) | Respiratory syncytial virus (rsv) vaccine | |
| Yan et al. | Icariin ameliorates memory deficits through regulating brain insulin signaling and glucose transporters in 3× Tg-AD mice | |
| EA201171439A1 (ru) | Соединение альфа-(n-сульфонамидо)ацетамида в качестве ингибитора продуцирования бета-амилоидного пептида | |
| BR112021007476A2 (pt) | Compostos e métodos para reduzir a expressão de príon | |
| Kozin et al. | Anti-amyloid therapy of Alzheimer’s disease: Current state and prospects | |
| Zhang et al. | Relationship among α‑synuclein, aging and inflammation in Parkinson's disease | |
| WO2013120628A8 (en) | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen | |
| HRP20191342T1 (hr) | Anti-phf-tau antitijela i njihove upotrebe | |
| JP2010535153A5 (de) | ||
| WO2010115843A3 (en) | Pharmaceutical composition | |
| WO2012036433A3 (ko) | miRNA를 타겟으로 한 신경퇴행성 질환 치료 | |
| Hannaoui et al. | Cycline efficacy on the propagation of human prions in primary cultured neurons is strain-specific | |
| Senatore et al. | Synaptic dysfunction in prion diseases: a trafficking problem? | |
| WO2008157425A3 (en) | Compounds for inhibiting protein aggregation, and methods for making and using them | |
| Choi et al. | Uptake and degradation of protease-sensitive and-resistant forms of abnormal human prion protein aggregates by human astrocytes | |
| Zhang et al. | Ligustrazine attenuates hyperhomocysteinemia-induced alzheimer-like pathologies in rats | |
| JP2017538407A5 (de) | ||
| Catania et al. | A novel bio-inspired strategy to prevent amyloidogenesis and synaptic damage in Alzheimer’s disease | |
| ME02851B (de) | Verwendung von p3 aus bakteriophagenfusionsproteinen als amyloidbindemittel | |
| Resenberger et al. | Neuroprotective and neurotoxic signaling by the prion protein | |
| JP2013526705A5 (de) |